None listed
Conditions
Brief summary
Hip joint osteoarthritis (OA) is a debilitating disease that impacts quality of life, resulting in around 8000 joint replacements in New Zealand per annum. Nerve receptors in the hip capsule may be involved in fine-tuning the muscles surrounding the joint, and failure of this mechanism might be related to hip OA, but its role is unclear. This study aims to provide unique insight by using nerve-muscle control techniques to elucidate the potential role of the capsule in hip OA.
Interventions
The intervention will consist of a passive, sustained stretch at the hip joint. This will be done in one session. The stretch will be performed three times by a clinical researcher. Each stretch will be maintained for 3 minutes. This intervention will be delivered to asymptomatic participants during Phase I, and individuals with osteoarthritis during the Phase II. Participants will receive both interventions (i.e. stretch and active control). Participants will be randomly allocated to a sequence of intervention (i.e. stretch followed by active control or active control followed by stretch). During the stretch, participants will be positioned prone, with their knee at 90° of flexion. The hip will be internally rotated to its maximum range. This position will impose mechanical loading into the hip joint, and it is hypothesized that it will stimulate mechanoreceptors at the hip joint. There will be a 10 minute interval between the two conditions. The following directions will be used for placing electrodes: Rectus Femoris: midpoint 50% on the line from the ASIA to the superior part of the patella. Adductor Longus: four fingerbreadths from the pubic tubercule into the muscle belly – palpate the tendon. Gluteus Maximus: 50% on the line between the sacral vertebrae (midpoint of the base of the sacrum) and the greater trochanter. Biceps Femoris: 50% on the line between the ischial tuberosity and the lateral epicondyle of the tibia. Gluteus Medius: 50% on the line from the iliac crest to the trochanter. Tensor Fascia Lata: On the line from the anterior ASIS to the lateral femoral condyle in the proximal 1/6.
Sponsors
Study design
Eligibility
Inclusion criteria
Phase I: 24 asymptomatic individuals will be recruited. Phase II: a sample of 10 participants with hip OA will be recruited. Confirmation of hip OA diagnosis will be achieved by a combination of physical tests and radiological findings as per the American College of Rheumatology.
Exclusion criteria
Phase I: Participants will be excluded if they present any signs of disorders that potentially impact the structure and function of the hip joint. This will be confirmed by questionnaire and by clinical examination. (i) Hip, knee or ankle limited disorders, as assessed by functional test and passive range of motion with overpressure. (ii) Musculoskeletal lower limb or back disorders that required assessment or treatment in the last 6 months; (iii) Neurological impairment or condition affecting lower limb function (iv) Systemic inflammatory disease (e.g. rheumatoid arthritis) Phase II: (i) Musculoskeletal lower limb or back disorders that required assessment or treatment in the last 6 months; (ii) Primary complaint of gluteal tendinopathy (clinical diagnosis), low back pain or referred back pain; (iii) History of hip trauma or surgery (leading to secondary hip osteoarthritis) (iv) Knee joint replacement/known knee joint pathology/limited knee range of motion (<90° flexion) that may impact ability to perform the intervention (v) Corticosteroid use (oral or intra-articular) in the past 3 months (vi) Neurological impairment or condition affecting lower limb function (vii) Systemic inflammatory disease (e.g. rheumatoid arthritis)